Drug Trial Radar · NCT00843492
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
Last checked: Nov 20, 2026Latest source record: Mar 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,351
Actual
Start
Dec 2008
Primary completion
Jan 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 13, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by ultrasound, and pulmonary embolism (blood clots that migrate to the lungs) in patients with leg injuries below the knee that require a cast or other type of immobilization but not surgery.
Conditions
- Thrombosis, Venous
Interventions
Fondaparinux sodiumDrug
After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
NadroparinDrug
After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete MobilizationTime frame: Day 1 to complete mobilization plus 2 days (average of 35.9 study days)
Locations
122 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Agen, France
GSK Investigational Site
Angers, France
GSK Investigational Site
Antony, France
GSK Investigational Site
Argenteuil, France
GSK Investigational Site
Beauvais, France
GSK Investigational Site
Bobigny, France
GSK Investigational Site
Brest, France
GSK Investigational Site
Cergy-Pontoise, France
GSK Investigational Site
Clermont-Ferrand, France
GSK Investigational Site
Colmar, France
GSK Investigational Site
Créteil, France
GSK Investigational Site
Grenoble, France
GSK Investigational Site
Lille, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Mougins, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Orthez, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Pringy, France
GSK Investigational Site
Rennes, France
GSK Investigational Site
Roanne, France
GSK Investigational Site
Rouen, France
GSK Investigational Site
Saint-Pierre, France
GSK Investigational Site
Sainte Colombe Les Vienne, France
GSK Investigational Site
Saintes, France
GSK Investigational Site
Toulouse, France
GSK Investigational Site
Valenciennes, France
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, Germany
GSK Investigational Site
Erlangen, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Hamburg, Free and Hanseatic City of Hamburg, Germany
GSK Investigational Site
Hamburg, Free and Hanseatic City of Hamburg, Germany
GSK Investigational Site
Wiesbaden, Hesse, Germany
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.